SGMTSagimet Biosciences Inc.
What is the market doing?
No clear lean: nothing decisive, though a crowded short (+18% of shares).
Choppy, but holding above its 200-day average. Price is +30% vs its 200-day average.
A crowded short, settled Sep 30, 2026, about a week of normal trading to cover.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How SGMT is trading
Sagimet Biosciences Inc. is +29% over the past year while the S&P 500 is +16%: 13 points ahead of the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +30%
vs 200-day average · a clear uptrend
- RSI (14)
- 56
RSI (14) · neutral
- Below its 52-week high
- 14%
Below its 52-week high
Details›
- Last close2026-10-23
- $9.58
- 1 monthS&P 500 −0.94%
- +5.2%
- 1 yearS&P 500 +16%
- +29%
- vs 50-day average$9.96
- −3.8%
- 52-week high
- $11.16
- 52-week low
- $4.55
- Annualised volatility
- 101%
| Year | Return |
|---|---|
| 2026 (year to date) | +62% |
| 2025 | +32% |
| 2024 | −17% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 3 | 1 of 3 | +23% |
| Feb | 3 | 1 of 3 | −17% |
| Mar | 3 | 0 of 3 | −11% |
| Apr | 3 | 2 of 3 | +10% |
| May | 3 | 2 of 3 | +10% |
| Jun | 3 | 2 of 3 | +28% |
| Jul | 3 | 1 of 3 | +1.4% |
| Aug | 4 | 1 of 4 | −0.43% |
| Sep | 4 | 0 of 4 | −12% |
| Oct | 4 | 2 of 4 | +12% |
| Nov | 3 | 2 of 3 | −0.13% |
| Dec | 3 | 1 of 3 | +0.99% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.